About Us
|
contact Us
|
Sitemap
Call us: +1-855-455-8662
|
Home
Business Solutions
Business Research Reports
Business Consulting
On-site Implementation & Training Programs
Industry Trackers
Subscription Solutions
Industry Reports
News
Press
Login
Register
Home
Market Research
T-Cell Lymphoma Treatment Market Expected to Grow at 11.7% by 2032
T-Cell Lymphoma Treatment Market By Type (Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Cutaneous T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma, Others), By Drugs (Chemotherapy Drugs, Corticosteroids, Immunomodulators, Targeted Therapy Drugs, Gene Therapy Drugs) - Growth, Future Prospects & Competitive Analysis, 2024 – 2032
25 Dec 2018
Format
Request Sample
Report Summary
Table of contents
list of tables
list of figures
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global T-Cell Lymphoma Treatment Market
2.2. Global T-Cell Lymphoma Treatment Market, By Type, 2023 (US$ Million)
2.3. Global T-Cell Lymphoma Treatment Market, By Drugs, 2023 (US$ Million)
2.4. Global T-Cell Lymphoma Treatment Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023
3. T-Cell Lymphoma Treatment Market: Competitive Analysis
3.1. Market Positioning of Key T-Cell Lymphoma Treatment Market Vendors
3.2. Strategies Adopted by T-Cell Lymphoma Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032
4. T-Cell Lymphoma Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global T-Cell Lymphoma Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape
5. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Peripheral T-Cell Lymphoma
5.3.2. Anaplastic Large Cell Lymphoma
5.3.3. Angioimmunoblastic T-Cell Lymphoma
5.3.4. Cutaneous T-Cell Lymphoma
5.3.5. Adult T-Cell Leukemia/Lymphoma
5.3.6. Others (Lymphoblastic lymphoma, Enteropathy-associated intestinal T-cell lymphoma, and Extranodal T-cell lymphoma)
6. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Chemotherapy Drugs
6.3.1.1. Cyclophosphamide
6.3.1.2. Doxorubicin
6.3.1.3. Vincristine
6.3.1.4. Etoposide
6.3.1.5. Gemcitabine
6.3.1.6. Pralatrexate
6.3.1.7. Navelbine
6.3.1.8. Others (Oxaliplatin, Gemcitabine, Cholormethine, Methotrexate & Mechlorethamine)
6.3.2. Corticosteroids
6.3.2.1. Prednisone
6.3.2.2. Dexamethasone
6.3.3. Immunomodulators
6.3.3.1. Lenalodimide
6.3.3.2. Interferon alfa-2b
6.3.3.3. Cyclosporine
6.3.3.4. Imiquimod
6.3.3.5. Bexarotene
6.3.3.6. Tazarotene
6.3.3.7. Forodesine (Mundesine)
6.3.4. Targeted Therapy Drugs
6.3.4.1. Alemtuzumab
6.3.4.2. Belinostat
6.3.4.3. Brentuximab vedotin
6.3.4.4. Romidespin
6.3.4.5. Rituximab
6.3.4.6. Mogamulizumab
6.3.4.7. Nivolumab
6.3.5. Gene Therapy Drugs
6.3.5.1. Yescarta (axicabtagene ciloleucel)
6.3.5.2. Kymirah (tisagenlecleucel)
7. North America T-Cell Lymphoma Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
7.3. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
7.4.T-Cell Lymphoma Treatment Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
7.4.1.1.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
7.4.1.2.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
7.4.1.3.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
8. UK and European Union T-Cell Lymphoma Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
8.3. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
8.4.T-Cell Lymphoma Treatment Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
8.4.1.1.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
8.4.1.2.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
8.4.1.3.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
8.4.1.4.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
8.4.1.5.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
8.4.1.6.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
9. Asia Pacific T-Cell Lymphoma Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
9.3. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
9.4.T-Cell Lymphoma Treatment Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
9.4.1.1.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
9.4.1.2.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
9.4.1.3.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
9.4.1.4.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
9.4.1.5.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
9.4.1.6.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
10. Latin America T-Cell Lymphoma Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
10.3. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
10.4.T-Cell Lymphoma Treatment Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
10.4.1.1.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
10.4.1.2.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
10.4.1.3.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
11. Middle East and Africa T-Cell Lymphoma Treatment Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
11.3. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
11.4.T-Cell Lymphoma Treatment Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
11.4.1.1.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
11.4.1.2.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2022-2032, USD (Million)
11.4.1.3.2. T-Cell Lymphoma Treatment Market: By Drugs, 2022-2032, USD (Million)
12. Company Profile
12.1. Actelion Pharmaceuticals
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Spectrum Pharmaceuticals
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Bristol-Myers Squibb
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Shenzen ChipScreen Biosciences, Ltd.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Celgene Corporation
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Eisai, Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Genmab A/S
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Galderma S.A.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Kyowa Hakko Kirin Co., Ltd.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Novartis AG
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Neumedicines, Inc.
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Amgen, Inc.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
12.13. F. Hoffman La-Roche
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Portfolio
12.13.4. Strategic Initiatives
12.14. Seattle Genetics
12.14.1. Company Overview
12.14.2. Financial Performance
12.14.3. Product Portfolio
12.14.4. Strategic Initiatives
12.15. Soligenix, Inc.
12.15.1. Company Overview
12.15.2. Financial Performance
12.15.3. Product Portfolio
12.15.4. Strategic Initiatives
12.16. ZIOPHARM Oncology
12.16.1. Company Overview
12.16.2. Financial Performance
12.16.3. Product Portfolio
12.16.4. Strategic Initiatives
12.17. Medivir AB
12.17.1. Company Overview
12.17.2. Financial Performance
12.17.3. Product Portfolio
12.17.4. Strategic Initiatives
12.18. Kura Oncology, Inc.
12.18.1. Company Overview
12.18.2. Financial Performance
12.18.3. Product Portfolio
12.18.4. Strategic Initiatives
12.19. Aleron Therapeutics
12.19.1. Company Overview
12.19.2. Financial Performance
12.19.3. Product Portfolio
12.19.4. Strategic Initiatives
12.20. Autolus Therapeutics plc
12.20.1. Company Overview
12.20.2. Financial Performance
12.20.3. Product Portfolio
12.20.4. Strategic Initiatives
12.21. Innate Pharma
12.21.1. Company Overview
12.21.2. Financial Performance
12.21.3. Product Portfolio
12.21.4. Strategic Initiatives
12.22. miRagen Therapeutics, Inc.
12.22.1. Company Overview
12.22.2. Financial Performance
12.22.3. Product Portfolio
12.22.4. Strategic Initiatives
12.23. Trillium Therapeutics Inc.
12.23.1. Company Overview
12.23.2. Financial Performance
12.23.3. Product Portfolio
12.23.4. Strategic Initiatives
12.24. Bellicum Pharmaceuticals, Inc.
12.24.1. Company Overview
12.24.2. Financial Performance
12.24.3. Product Portfolio
12.24.4. Strategic Initiatives
12.25. Sorrento Therapeutics, Inc.
12.25.1. Company Overview
12.25.2. Financial Performance
12.25.3. Product Portfolio
12.25.4. Strategic Initiatives
Choose Licence Type
Single User Licence
$4325
Multi User license
$6325
Corporate license
$12650
Buy Now
Quick Contact
+1-855-455-8662
+91 77559-81103
sales@acutemarketreports.com
View Other Reports
Automotive
986
Chemicals and Materials
684
Consumer Goods
184
Energy
124
Food & Beverages
321
Medical Devices
178
Pharmaceutical & Healthcare
78
Technology
234